Home / Health / India's Thalassemia Fight: Prevention Over Cure
India's Thalassemia Fight: Prevention Over Cure
9 May
Summary
- India sees 10,000-12,000 Thalassemia Major births annually.
- Screening and genetic counseling empower informed reproductive choices.
- IVF with PGT-M offers high certainty for disease-free embryos.
World Thalassemia Day highlights India's substantial challenge with this genetic disorder, witnessing an estimated 10,000 to 12,000 births of Thalassemia Major annually. The current approach is evolving from managing severe, lifelong conditions requiring frequent transfusions, towards proactive prevention. This shift is powered by advancements in clinical understanding and reproductive technologies.
Carrier screening, a simple blood test, is the foundational step in prevention. Beta thalassemia is an autosomal recessive condition where two carriers have a 25% risk of affected offspring. While carriers often remain asymptomatic, their children can be severely impacted. India's National Health Mission recommends antenatal screening and genetic counseling.
For couples identified as carriers, reproductive medicine offers advanced solutions. In Vitro Fertilization (IVF) combined with Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) allows for the screening of embryos for specific genetic mutations before implantation. This technology provides a high level of certainty in preventing the birth of children with Thalassemia Major.
The pathway to prevention is clear and achievable. It involves systematic pre-conception carrier identification and the availability of reproductive options like PGT-M. These strategies represent a crucial advancement for families and the healthcare system in combating India's thalassemia burden.
